ReviewCritical care (London, England)2026
Sepsis-related immunosuppression: a comprehensive review of current research breakthroughs.
Review in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article focuses on Sepsis-related immunosuppression, systematically expounding on its pathological mechanisms, monitoring methods, and treatment strategies. Immunosuppression in sepsis involves multi-level functional exhaustion of the innate and adaptive immune systems, such as dysfunctions of monocytes/macrophages, neutrophils, and dendritic cells, depletion of T and B cells, and imbalance of the cytokine network. The monitoring of the immune state mainly relies on the detection of the quantity and function of immune cells, HLA-DR expression, and cytokine levels. Treatment methods include immunostimulation (such as IL-7, GM-CSF), immune checkpoint inhibitors, other immunomodulatory therapies (such as IFN-γ, mesenchymal stem cells), and intravenous immunoglobulin. However, the clinical transformation effects of existing treatment strategies remain to be verified. In-depth research on sepsis-related immunosuppression is of great significance for improving clinical diagnosis and treatment and reducing mortality.Importantly, the pathogenesis and trajectory of immunosuppression in children differ significantly from adults due to age‑specific immune development, necessitating a separate discussion of pediatric‑specific mechanisms and monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.